Reprocell and Fox Chase to open biosample repository in India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Reprocell USA, a subsidiary of Japan’s Reprocell Inc., and Fox Chase Ltd., one of the Fox Chase Cancer Center organizations, formed a joint venture to operate a multi-site bio-sample repository facility in India.

Initial operations are underway in Delhi with plans to expand to Hyderabad later this year. The facilities will add approximately 3,000 new bio-samples monthly. Collected specimens will be supported by annotations that include medical history, mutation data and detailed records of treatment protocols as well as outcomes.

YOU MAY BE INTERESTED IN

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login